After Hours Gainer
SLDB Solid Biosciences5.24-0.05-1.0%
After Hours:5.41+0.17 (+3.2%)
Solid Biosciences Receives FDA Orphan Drug Designation for SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich's Ataxia
Globe NewswireMon, 12-Jan 4:15 PM
After Hours:5.53+0.29 (+5.5%)
SLDB Solid Biosciences5.82+0.11+1.9%
After Hours:6.03+0.21 (+3.6%)
Solid Biosciences Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services
Globe NewswireTue, 16-Dec 4:51 PM
SLDB Solid Biosciences6.55+1.25 (+23.6%)
SLDB Solid Biosciences5.94+1.91 (+47.4%)
SLDB Solid Biosciences3.19+0.05 (+1.6%)
